Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | IGNYTE: efficacy of RP1 & nivolumab in superficial & visceral melanoma lesions

Gino In • 30 May 2025
ASCO 2025
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors Nivolumab Vusolimogene oderparepvec
IGNYTE

Gino In, MD, MPH, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, discusses the IGNYTE trial (NCT03767348) of vusolimogene oderparepvec (RP1) plus nivolumab in anti-PD-1-refractory melanoma. Both injected and non-injected lesions, including visceral tumors, demonstrated similarly meaningful reductions, supporting systemic activity. Efficacy outcomes were consistent across superficial and deep/visceral injection groups. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gino In

How can we overcome anti-PD-1 resistance in melanoma?
0:46
How can we overcome anti-PD-1 resistance in melanoma?
Gino In • 30 May 2025
Efficacy of RP1, an engineered oncolytic virus, in the treatment of melanoma
0:42
Efficacy of RP1, an engineered oncolytic virus, in the treatment of melanoma
Gino In • 30 May 2025
IGNYTE: RP1 with nivolumab in anti-PD1-resistant melanoma
3:43
IGNYTE: RP1 with nivolumab in anti-PD1-resistant melanoma
Gino In • 22 Oct 2024
Advances in oncolytic immunotherapy for melanoma: vusolimogene oderparepvec
3:54
Advances in oncolytic immunotherapy for melanoma: vusolimogene oderparepvec
Gino In • 22 Oct 2024

Related Videos

Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
3:13
Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
Omid Hamid • 30 May 2026
ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma
1:32
ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma
Omid Hamid • 30 May 2026
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
0:55
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
Omid Hamid • 30 May 2026
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The content of VJOncology is intended for healthcare professionals